The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Telfast 180 mg film-coated tablets

Opella Healthcare France SAS T/A SanofiPA23180/003/003

Main Information

Trade NameTelfast 180 mg film-coated tablets
Active SubstancesFexofenadine hydrochloride
Dosage FormFilm-coated tablet
Licence HolderOpella Healthcare France SAS T/A Sanofi
Licence NumberPA23180/003/003

Group Information

ATC CodeR06AX Other antihistamines for systemic use
R06AX26 fexofenadine


License statusAuthorised
Licence Issued11/11/1997
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back